A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their ...

Among a cohort of patients with severe asthma using the biologic therapy benralizumab, 92% could safely reduce inhaled steroid dose and more than 60% could stop all use.

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published ...

A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has ...

Of the 158 patients, 54% were female and 46% were male, aged between 18 and 84 and with a mean age of 57. There were 53 patients in the steroid group, 53 in the Fasenra group, and 52 in the ...